UNION CITY, Calif., Dec. 2, 2008 (GLOBE NEWSWIRE) -- Questcor Pharmaceuticals, Inc. (NasdaqCM:QCOR - News) announced that it has resubmitted to the U.S. Food & Drug Administration (FDA) its supplemental New Drug Application (sNDA) seeking approval to market H.P. Acthar(r) Gel (repository corticotrophin injection) for the treatment of infantile spasms.
